PMID- 35221761
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220502
IS  - 0513-5710 (Print)
IS  - 1346-8049 (Electronic)
IS  - 0513-5710 (Linking)
VI  - 65
IP  - 1
DP  - 2022 Feb
TI  - Predictive Model for Adverse Events and Immune Response Based on the Production 
      of Antibodies After the Second-Dose of the BNT162b2 mRNA Vaccine.
PG  - 63-69
LID - 10.33160/yam.2022.02.012 [doi]
AB  - BACKGROUND: The BNT162b mRNA vaccine for coronavirus disease 2019, which is 
      caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), mimics 
      the immune response to natural infection. Few studies have predicted the adverse 
      effects (AEs) after the second-dose vaccination. We present a predictive model 
      for AEs and immune response after the second-dose of the BNT162b mRNA vaccine. 
      METHODS: To predict AEs, 282 healthcare workers (HCWs) were enrolled in this 
      prospective observational study. The classification and regression tree (CART) 
      model was established, and its predictive efficacy was assessed. To predict 
      immune response, 282 HCWs were included in the analysis. Moreover, the factors 
      affected by anti-SARS-CoV-2 spike protein RBD antibody (s-IgG) were evaluated 
      using serum samples collected 2 months after the second-dose vaccination. The 
      s-IgG level was assessed using Lumipulse G1200. Multiple regression analyses were 
      conducted to evaluate variables associated with anti-s-IgG titer levels. RESULTS: 
      The most common AEs after the second-dose vaccination were pain (87.6%), redness 
      (17.0%) at the injection site, fatigue (68.8%), headache (53.5%), and fever 
      (37.5%). Based on the CART model, headache after the first-dose vaccination and 
      age < 30 years were identified as the first and second discriminators for 
      predicting the headache after the second-dose vaccination, respectively. In the 
      multiple linear regression model, anti-s-IgG titer levels were associated with 
      age, female sex, and AEs including headache and induration at the injection site 
      after the second-dose vaccination. CONCLUSION: Headache after the first-dose 
      vaccination can be a predictor of headache after the second-dose vaccination, and 
      AEs are indicators of immune response.
CI  - (c)2022 Tottori University Medical Press.
FAU - Okada, Shinichi
AU  - Okada S
AD  - Department of Pediatrics, National Hospital Organization Yonago Medical Center, 
      Yonago 683-0006, Japan.
FAU - Tomita, Katsuyuki
AU  - Tomita K
AD  - Department of Respiratory Medicine, National Hospital Organization Yonago Medical 
      Center, Yonago 683-0006, Japan.
FAU - Inui, Genki
AU  - Inui G
AD  - Department of Respiratory Medicine, National Hospital Organization Yonago Medical 
      Center, Yonago 683-0006, Japan.
FAU - Ikeuchi, Tomoyuki
AU  - Ikeuchi T
AD  - Department of Respiratory Medicine, National Hospital Organization Yonago Medical 
      Center, Yonago 683-0006, Japan.
FAU - Touge, Hirokazu
AU  - Touge H
AD  - Department of Respiratory Medicine, National Hospital Organization Yonago Medical 
      Center, Yonago 683-0006, Japan.
FAU - Hasegawa, Junichi
AU  - Hasegawa J
AD  - Department of Internal Medicine, National Hospital Organization Yonago Medical 
      Center, Yonago 683-0006, Japan.
FAU - Yamasaki, Akira
AU  - Yamasaki A
AD  - Division of Respiratory Medicine and Rheumatology, Department of 
      Multidisciplinary Internal Medicine, School of Medicine, Faculty of Medicine, 
      Tottori University, Yonago 683-8503, Japan.
LA  - eng
PT  - Journal Article
DEP - 20220222
PL  - Japan
TA  - Yonago Acta Med
JT  - Yonago acta medica
JID - 0414002
PMC - PMC8857677
OTO - NOTNLM
OT  - BNT162b2 vaccine
OT  - adverse effect
OT  - antibody
OT  - classification and regression tree
COIS- The authors declare no conflicts of interest.
EDAT- 2022/03/01 06:00
MHDA- 2022/03/01 06:01
PMCR- 2022/02/22
CRDT- 2022/02/28 05:32
PHST- 2021/10/25 00:00 [received]
PHST- 2022/01/05 00:00 [accepted]
PHST- 2022/02/28 05:32 [entrez]
PHST- 2022/03/01 06:00 [pubmed]
PHST- 2022/03/01 06:01 [medline]
PHST- 2022/02/22 00:00 [pmc-release]
AID - 2022.02.012 [pii]
AID - 10.33160/yam.2022.02.012 [doi]
PST - epublish
SO  - Yonago Acta Med. 2022 Feb 22;65(1):63-69. doi: 10.33160/yam.2022.02.012. 
      eCollection 2022 Feb.